The business of animal health has traditionally been dominated by the animal health divisions of big pharma companies. But with Pfizer’s 2013 spin-off of its animal health business, now known as Zoetis, the sector has been undergoing fundamental changes that
Life Sciences Legal Insights
Insight and analysis on important legal issues affecting life sciences, mHealth, digital health and healthcare IT.
Life Sciences Legal Insights, published by Fenwick & West LLP, focuses on legal developments and business trends affecting the life sciences sector. The blog covers topics such as digital health innovations, pharmaceutical and biotech IPOs, regulatory and compliance issues, intellectual property matters including patent litigation, and the impact of emerging technologies on healthcare delivery. It also addresses market dynamics like venture capital funding, SPAC transactions, and mergers and acquisitions within life sciences. The content includes analysis of legal challenges faced by startups and established companies, as well as strategic considerations for growth and exit opportunities in the life sciences industry.
Latest from Life Sciences Legal Insights - Page 3
Digital Health Investment Levels Off and Unicorns Emerge
In its Q1 2019 digital health funding report Rock Health noted that investment in digital health companies leveled off in the first quarter after a record-setting 2018. At $986 million, investment in the first three months of the year was…
Which Way to the Exits for Biotech?
The Year of the Megadeal and a Hot Digital Health Market in China
No matter who is doing the counting, 2018 was an off-the-charts year for venture investment in digital health. Here’s a sampling of the tallies:
- Our good friends at Rock Health put the total investment at $8.1 billion – an impressive
…
How AI is Transforming Healthcare: Diagnostics, R&D and Therapeutics
Takeaways from Fenwick’s 2018 Digital Health Investor Summit
Digital Health Megadeals Get Bigger in Q3 2018
Just over a year ago, we reported about the rise of the mega-round in digital health investments. At that time, we tallied nine investment rounds valued at more than $100 million in the first half of 2017. Deals in H1…
Digital Health Investment Trends Q2 2018: Megadeals Become the Norm, China Rising
Investors Make Big Bets on Diagnostics in Q1 2018
Two trends stood out in our analysis of private digital health investments in the first quarter of 2018: bigger deals and more investment in companies targeting the regulated portion of the health care market.
As the digital health sector matures,…
JPM Conference Takeaways: Biotech and Biopharma Set for Growth in 2018
Coming off a year that saw a record number of new drug approvals, significant scientific breakthroughs and a year-end tax reform package that both significantly lowers corporate taxes and provides the long-awaited tax repatriation holiday, it’s not surprising that biotech…